Methods and compositions relating to the treatment of cancer
US-2015374692-A1 · Dec 31, 2015 · US
Polypeptide and lipophilic moiety conjugate compositions, formulations, and uses related thereto
US9878054B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9878054-B2 |
| Application number | US-201314403187-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 17, 2013 |
| Priority date | May 18, 2012 |
| Publication date | Jan 30, 2018 |
| Grant date | Jan 30, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
In certain embodiments, this disclosure relates to pharmaceutical formulations for polypeptide and lipophilic moiety conjugates suitable for injection into humans and other animals and methods of preparation. In certain embodiments, the disclosure relates to a method of preparing the formulation comprising lyophilizing, solubilizing in ammonium acetate, filtering to create mono-disperse particles, re-lyophilizing, and solubilizing the micelles in a dextrose solution for injection.
First claim
Opening claim text (preview).
What I claim: 1. A pharmaceutical composition comprising micelles of palmitate-KKSRALF-NH 2 (palmitate-SEQ ID NO:2-NH 2 ) acid salts and an aqueous solution comprising dextrose at about 5% by weight. 2. The pharmaceutical composition of claim 1 , wherein the palmitate-KKSRALF-NH 2 acid salts are in the form of acetic acid salts.
Assignees
Inventors
Classifications
Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)} · CPC title
- A61K47/6907Primary
the form being a microemulsion, nanoemulsion or micelle · CPC title
Carboxylic acids, e.g. a fatty acid or an amino acid · CPC title
Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin · CPC title
Receptors; Cell surface antigens; Cell surface determinants · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9878054B2 cover?
- In certain embodiments, this disclosure relates to pharmaceutical formulations for polypeptide and lipophilic moiety conjugates suitable for injection into humans and other animals and methods of preparation. In certain embodiments, the disclosure relates to a method of preparing the formulation comprising lyophilizing, solubilizing in ammonium acetate, filtering to create mono-disperse particl…
- Who is the assignee on this patent?
- Tufts Medical Ct Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K47/6907. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 30 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).